Literature DB >> 15232691

[Eradication and chronic acid suppression. Advances and pseudo-advances].

S Turi1, D Schilling, J F Riemann.   

Abstract

Guidelines for Helicobacter pylori therapy were proposed at the Maastricht 2/2000 conference. Since then no further major developments have been made. An evidenced based choice of treatment is thereby nearly impossible as large randomized trials have not been performed. Minor progress could be achieved in the areas of second-line and rescue treatment options after failure of the standard therapy. At present proton pump inhibitors are the most powerful drugs for the treatment of gastro-oesophageal reflux disease. No additional progress has been achieved concerning therapy of reflux disease in the last years. Reasonable anxiety about the safety of long-term acid suppression with proton pump inhibitors diminished over years as no significant increase in cancer development could be detected.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15232691     DOI: 10.1007/s00108-004-1237-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  35 in total

1.  Increasing concerns about chronic proton pump inhibitor use.

Authors:  A C Svoboda
Journal:  J Clin Gastroenterol       Date:  2001-07       Impact factor: 3.062

Review 2.  Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.

Authors:  C A Stedman; M L Barclay
Journal:  Aliment Pharmacol Ther       Date:  2000-08       Impact factor: 8.171

3.  The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole.

Authors:  J Huang; R H Hunt
Journal:  Aliment Pharmacol Ther       Date:  1999-06       Impact factor: 8.171

Review 4.  Helicobacter pylori therapy: first-line options and rescue regimen.

Authors:  J P Gisbert; J M Pajares
Journal:  Dig Dis       Date:  2001       Impact factor: 2.404

Review 5.  An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews.

Authors:  Paul Moayyedi; Jon Deeks; Nicholas J Talley; Brendan Delaney; David Forman
Journal:  Am J Gastroenterol       Date:  2003-12       Impact factor: 10.864

Review 6.  Eradication of Helicobacter pylori for non-ulcer dyspepsia.

Authors:  P Moayyedi; S Soo; J Deeks; B Delaney; A Harris; M Innes; R Oakes; S Wilson; A Roalfe; C Bennett; D Forman
Journal:  Cochrane Database Syst Rev       Date:  2003

Review 7.  What constitutes failure for Helicobacter pylori eradication therapy?

Authors:  P Malfertheiner; U Peitz; G Treiber
Journal:  Can J Gastroenterol       Date:  2003-06       Impact factor: 3.522

Review 8.  Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts.

Authors:  F Parente; C Cucino; G Bianchi Porro
Journal:  Dig Liver Dis       Date:  2003-08       Impact factor: 4.088

9.  Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication.

Authors:  M Vergara; M Vallve; J P Gisbert; X Calvet
Journal:  Aliment Pharmacol Ther       Date:  2003-09-15       Impact factor: 8.171

10.  The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency.

Authors:  B-S Sheu; J-J Huang; H-B Yang; A-H Huang; J-J Wu
Journal:  Aliment Pharmacol Ther       Date:  2003-05-15       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.